Search Result

Results for "

Rivastigmine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cholinesterase (ChE) (11) Drug Intermediate (1) Isotope-Labeled Compounds (6)
By Research Areas:	Neurological Disease (11)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17368

*Rivastigmine* 1 Publications Verification ENA 713 free base; SDZ-ENA 713 free base	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W020576

Rivastigmine metabolite NAP 226-90	Cholinesterase (ChE) Others	Neurological Disease
Rivastigmine metabolite (NAP 226-90) is an acetylcholinesterase (AChE) inhibitor which is produced in kidney. Rivastigmine metabolite is promising for research of Alzheimer’s Disease .

HY-133776

Rivastigmine carbamate impurity 3-Nitrophenyl ethyl(methyl)carbamate	Cholinesterase (ChE)	Neurological Disease
Rivastigmine carbamate impurity (3-Nitrophenyl ethyl(methyl)carbamate) is an impurity of Rivastigmine. Rivastigmine is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively .

HY-11017

Rivastigmine tartrate 1 Publications Verification ENA 713; SDZ-ENA 713	Cholinesterase (ChE)	Neurological Disease
Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W020576R

Rivastigmine metabolite (Standard)	Others	Neurological Disease
Rivastigmine metabolite (Standard) is the analytical standard of Rivastigmine metabolite. This product is intended for research and analytical applications. Rivastigmine metabolite is an acetylcholinesterase (AChE) inhibitor which is produced in kidney. Rivastigmine metabolite is promising for research of Alzheimer’s Disease .

HY-W654335

Rivastigmine-d4 tartrate	Isotope-Labeled Compounds Cholinesterase (ChE)	Neurological Disease
Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S2

Rivastigmine-d3 hydrochloride ENA 713-d₃ hydrochloride; SDZ-ENA 713-d₃ hydrochloride	Cholinesterase (ChE) Isotope-Labeled Compounds	Neurological Disease
Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-11017R

Rivastigmine (tartrate) (Standard) ENA 713 (Standard); SDZ-ENA 713 (Standard)	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (tartrate) (Standard) is the analytical standard of Rivastigmine (tartrate). This product is intended for research and analytical applications. Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368R

Rivastigmine (Standard) ENA 713 (free base)(Standard); SDZ-ENA 713 (free base)(Standard)	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (Standard) is the analytical standard of Rivastigmine. This product is intended for research and analytical applications. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W020576S

Rivastigmine metabolite-d6 NAP 226-90-d₆	Isotope-Labeled Compounds	Others
(S)-3-(1-(Dimethylamino)ethyl)phenol-d6 is the deuterium labeled Rivastigmine metabolite(HY-W020576) .

HY-W654336

*(S)-Rivastigmine-d4*	Isotope-Labeled Compounds Cholinesterase (ChE)	Neurological Disease
(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-11017AS

*(S)-Rivastigmine-d6 tartrate*	Cholinesterase (ChE)	Others
(S)-Rivastigmine-d₆ (tartrate) is the deuterium labeled (S)-Rivastigmine, which is an cholinesterase inhibitor.

HY-144154S

*(Rac)-Rivastigmine-d6 tartrate*	Isotope-Labeled Compounds	Others
(Rac)-Rivastigmine-d₆ (tartrate) is the deuterium labeled (Rac)-Rivastigmine tartrate[1].

HY-17368S1

*(Rac)-Rivastigmine-d6* (Rac)-ENA 713-d₆ free base; (Rac)-SDZ-ENA 713-d₆ free base	Isotope-Labeled Compounds Cholinesterase (ChE)	Neurological Disease
(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

HY-Y0603

3-Hydroxyacetophenone m-Hydroxyacetophenone	Drug Intermediate	Others
3-Hydroxyacetophenone (m-Hydroxyacetophenone) is the hydroxy-substituted alkyl phenyl ketone that can be used in synthesis of enantiopure (-)-rivastigmine .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Y0603

3-Hydroxyacetophenone m-Hydroxyacetophenone	Structural Classification Monophenols other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Phenols Plants Disease Research Fields	Drug Intermediate
3-Hydroxyacetophenone (m-Hydroxyacetophenone) is the hydroxy-substituted alkyl phenyl ketone that can be used in synthesis of enantiopure (-)-rivastigmine .

Cat. No.	Product Name	Chemical Structure

HY-11017AS

*(S)-Rivastigmine-d6 tartrate*
(S)-Rivastigmine-d₆ (tartrate) is the deuterium labeled (S)-Rivastigmine, which is an cholinesterase inhibitor.

HY-W654335

Rivastigmine-d4 tartrate
Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Rivastigmine-d4 tartrate

Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S2

Rivastigmine-d3 hydrochloride
Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Rivastigmine-d3 hydrochloride

Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W020576S

Rivastigmine metabolite-d6
(S)-3-(1-(Dimethylamino)ethyl)phenol-d6 is the deuterium labeled Rivastigmine metabolite(HY-W020576) .

HY-W654336

*(S)-Rivastigmine-d4*
(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

(S)-Rivastigmine-d4

(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-144154S

*(Rac)-Rivastigmine-d6 tartrate*
(Rac)-Rivastigmine-d₆ (tartrate) is the deuterium labeled (Rac)-Rivastigmine tartrate[1].

HY-17368S1

*(Rac)-Rivastigmine-d6*
(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

(Rac)-Rivastigmine-d6

(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks